Axsome Therapeutics (AXSM)
(Real Time Quote from BATS)
$92.13 USD
-3.71 (-3.87%)
Updated Sep 23, 2024 11:53 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Company Summary
New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of the central nervous system, disorders for which there are limited treatment options available.
Auvelity (AXS-05) is approved for the treatment of adults with major depressive disorder (MDD). It is the first approved drug in Axsome’s portfolio. Auvelity was launched in the United States in 2022. AXS-05 is also being studied for agitation associated with Alzheimer’s disease and smoking cessation.
Other pipeline candidates in the company&...
Company Summary
New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of the central nervous system, disorders for which there are limited treatment options available.
Auvelity (AXS-05) is approved for the treatment of adults with major depressive disorder (MDD). It is the first approved drug in Axsome’s portfolio. Auvelity was launched in the United States in 2022. AXS-05 is also being studied for agitation associated with Alzheimer’s disease and smoking cessation.
Other pipeline candidates in the company’s portfolio include AXS-07, AXS-09, AXS-12, and AXS-14, which are being developed for multiple CNS indications.
In April 2022, Axsome received a complete response letter (CRL) for an NDA seeking approval for AXS-07 for the acute treatment of migraine. The company resubmitted the NDA for AXS-07 in September 2024. A decision from the FDA is due on Jan. 31, 2025.
AXS-12 is being studied for the treatment of narcolepsy and AXS-14 (esreboxetine) for fibromyalgia. Axsome obtained exclusive U.S. rights for AXS-14 from Pfizer in January 2020.
Axsome completed its acquisition of a commercialized drug targeting narcolepsy, Sunosi, from Jazz in May 2022. In February 2023, Axsome entered a licensing agreement with Pharmanovia out-licensing marketing rights to Sunosi in European and certain Middle East North African countries.
Axsome generated total revenues of $270.6 million in 2023, significantly up year over year.
General Information
Axsome Therapeutics, Inc
One World Trade Center 22nd Floor
NEW YORK, NY 10007
Phone: 212-332-3241
Fax: 212-320-0245
Web: http://axsome.com
Email: NA
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/4/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.36 |
Current Year EPS Consensus Estimate | -5.56 |
Estimated Long-Term EPS Growth Rate | 35.10 |
Exp Earnings Date | 11/4/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 95.84 |
52 Week High | 98.40 |
52 Week Low | 55.02 |
Beta | 1.25 |
20 Day Moving Average | 413,164.84 |
Target Price Consensus | 125.82 |
4 Week | 8.92 |
12 Week | 19.06 |
YTD | 20.42 |
4 Week | 7.62 |
12 Week | 14.00 |
YTD | 0.72 |
Shares Outstanding (millions) | 47.50 |
Market Capitalization (millions) | 4,552.00 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -24.00% |
vs. Previous Quarter | -13.76% |
vs. Previous Year | 86.65% |
vs. Previous Quarter | 16.22% |
Price/Book | 44.26 |
Price/Cash Flow | NA |
Price / Sales | 15.62 |
6/30/24 | -117.46 |
3/31/24 | -87.17 |
12/31/23 | -70.67 |
6/30/24 | -36.39 |
3/31/24 | -32.81 |
12/31/23 | -27.47 |
6/30/24 | 2.48 |
3/31/24 | 3.20 |
12/31/23 | 3.63 |
6/30/24 | 2.40 |
3/31/24 | 3.09 |
12/31/23 | 3.52 |
6/30/24 | -71.26 |
3/31/24 | -76.68 |
12/31/23 | -55.57 |
6/30/24 | -105.85 |
3/31/24 | -118.07 |
12/31/23 | -88.41 |
6/30/24 | -106.20 |
3/31/24 | -118.71 |
12/31/23 | -88.06 |
6/30/24 | 2.17 |
3/31/24 | 3.03 |
12/31/23 | 4.04 |
6/30/24 | 2.02 |
3/31/24 | 1.99 |
12/31/23 | 2.46 |
6/30/24 | 1.77 |
3/31/24 | 1.25 |
12/31/23 | 0.93 |
6/30/24 | 63.94 |
3/31/24 | 55.60 |
12/31/23 | 48.25 |